The Use of Alpha-adrenergic Blockers in Benign Prostatic Obstrucion

Abstract

As a result of previous in-vitro studies on the alpha-adrenergic receptor activity of the human prostate and prostatic capsule a trial was made of alpha-adrenergic blockers for the relief of obstructive prostatic symptoms. Considerable benefit was obtained in several groups of patients, as demonstrated either by the relief or prevention of complete retention, or by diminution in residual urine or improvement in urinary flow-rate recordings. A number of illustrative cases are described, and the indications for the use of this treatment are suggested. It is emphasised that this treatment provides symptomatic relief only, and in no sense purports to be a treatment of the enlarged prostate itself.

Induction of prostate apoptosis by α1-adrenoceptor antagonists: mechanistic significance of the quinazoline component

“…21 Targeting these receptors as a means of preventing smooth muscle contraction gave rise to a class of medications commonly used to treat LUTS. 22,23 There are currently four recognized subtypes of a-adrenoceptors identified in the prostate: a 1a , a 1b , a 1d and a 1L . 24 -26 Classically, a 1 -adrenoceptor antagonists have been used to target the stromal smooth muscle cells in the treatment of BPH in order to reduce their tone.…”

Clinical Uroselectivity of Alfuzosin in the Treatment of Benign Prostatic Hyperplasia

“…By antagonizing the effect of noradrenaline at the α 1 -adrenoceptor, α 1 -blockers reduce smooth muscle cell tone in the bladder neck, prostatic urethra, prostate capsule and prostatic adenoma [2, 3]. The consequence of this is a reduction in the dynamic component of bladder outlet obstruction.…”

“…The application of α 1 -blockers for the relief of bladder outlet obstruction due to BPH was first proposed by Caine et al [2] 1976. By antagonizing the effect of noradrenaline at the α 1 -adrenoceptor, α 1 -blockers reduce smooth muscle cell tone in the bladder neck, prostatic urethra, prostate capsule and prostatic adenoma [2, 3].…”

A Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia

“…As life expectancy is increasing, the number of patients with symptomatic BPH is also increasing.The clinical manifestation of BPH included lower urinary tract symptoms, poor bladder emptying, urinary retention, detrusor instability, urinary tract infection, haematuria and renal insufficiency. Dynamic obstruction is caused by increased muscle tone of the bladder neck and prostate which is regulated by alpha1 adrenergic receptor 4 .…”